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Abstract
Background. Renal transplantation is the best therapy for
patients with hepatitis C virus (HCV) infection with end-
stage renal disease. Patient and graft survival are lower in
the long term compared with HCV-negative patients. The
current study evaluated the results of renal transplantation
in Spain in a long period (1990–2002), focusing on graft
failure.
Methods. Data on the Spanish Chronic Allograft Ne-
phropathy Study Group including 4304 renal transplant re-
cipients, 587 of them with HCV antibody, were used to
estimate graft and patient survival at 4 years with multivar-
iate Cox models.
Results. Among recipients alive with graft function 1year
post-transplant, the 4-year graft survival was 92.8% in the
whole group; this was significantly better in HCV-negative
vs HCV-positive patients (94.4% vs 89.5%, P < 0.005).
Notably, HCV patients showed more acute rejection, a
higher degree of proteinuria accompanied by a diminution
of renal function, more graft biopsies and lesions of de
novo glomerulonephritis and transplant glomerulopathy.
Serum creatinine and proteinuria at 1 year, acute rejection,
HCV positivity and systolic blood pressure were indepen-
dent risk factors for graft loss. Patient survival was 96.3%
in the whole group, showing a significant difference be-
tween HCV-negative vs HCV-positive patients (96.6% vs
94.5%, P < 0.05). Serum creatinine and diastolic blood
pressure at 1 year, HCV positivity and recipient age were
independent risk factors for patient death.
Conclusions. Renal transplantation is an effective thera-
py for HCV-positive patients with good survival but in-
ferior than results obtained in HCV-negative patients in
the short term. Notably, HCV-associated renal damage
appears early with proteinuria, elevated serum creatinine
showing chronic allograft nephropathy, transplant glo-
merulopathy and, less frequently, HCV-associated de
novo glomerulonephritis. We suggest that HCV infection
should be recognized as a true risk factor for graft fail-
ure, and preventive measures could include pre-transplant
therapy with interferon.
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Introduction
Renal transplantation is the best therapeutic option for hep-
atitis C virus-positive (HCV) patients with end-stage renal
disease [1,2]. However, graft and patient survival are lower
in most series comparing with patients without HCV infec-
tion [3–5]. In fact, HCV infection is an independent risk
factor for mortality, and also for graft loss [5,6]. In this
way, although the presence of HCV-related post-transplant
complications such as glomerulonephritis and diabetes can
contribute to graft loss, why HCV infection negatively in-
fluences graft survival is unknown. In spite of these, results
after renal transplantation in HCV patients are better than
those obtained in HCV patients in the waiting list [1,3].
We previously published the influence of HCV infec-
tion on late graft loss in Spain including the period
1990–98, demonstrating that HCV infection was an inde-
pendent risk factor for graft loss and mortality [5]. In this
way, the decreasing incidence of the prevalence of HCV
infection was an important factor together with the low
incidence of acute rejection to improve the results from
1990 to 1998 in our country. Now, we extended the data
of chronic allograft study to include the year 2002 that
represents a time with modern immunosuppression. We
analysed the results of renal transplantation in HCV pa-
tients during the period 1990–2002 focusing on graft loss
and their causes. We also compared two periods, 1990–94
vs 1998–2002.
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Sources of data
The data on recipients were collected from individual transplant centres
participating in the Spanish Chronic Allograft Nephropathy Study Group,
which comprised 34 out of 38 adult kidney transplant centres in Spain and
96% of all adult kidney transplant recipients in Spain who were alive with
a functioning graft at 1year post-transplant, during the studied years
(1990, 1994, 1998 and 2002).
Study population
According to the Spanish National Transplant Organization (ONT), total
cases of transplanted patients in the years 1990, 1994, 1998 and 2002 were
6901(source:www.ont.msc.es),ofwhich5060(73.3%oftotal)transplants
were included by the 34 centres participating in the study. The inclusion
criteria were to be recipients of a single organ with a functioning graft at
1 year post-transplant and more than 2 years of follow-up. We found 89
(1.8%) patients younger than 18 years. Furthermore, 91 (1.8%) cases were
excluded for having an inferior graft survival at 1 year. Eighty-six (1.7%)
patients were not included because no data were available for monitoring,
and therefore, the total number of patients analysed was 4842 (95.7%).
Distribution of patients according to the serology for hepatitis C and B
virus was the following: 97.5% of patients (n = 4304) did not have hep-
atitis B virus, of which 13.6% (n = 587) presented HCV+ and the remain-
ing 86.4% (n = 3717) HCV−.
Methods
For the following analysis, we have taken into account all evaluable pa-
tients not showing HBV+ (n = 4304), disaggregated by the year of trans-
plantation: 1990–94 (n = 1659, 38.5%) vs. 1998–2002 (n = 2645, 61.5%).
To avoid the need to adjust survival per year of transplant, given that mon-
itoring of patients is significantly higher in those transplanted between
1990 and 1994 than in those transplanted between 1998 and 2002 (and
as its follow-up varies from 16–12 years to 8–4 years, respectively), graft
and patient survival were examined during the first 4 years after transplan-
tation. Thus, patients whose graft or patient survivalwas more than 4 years
were only assessed until the fourth year after transplantation.
Definitions
The glomerular filtration rate (GFR) was estimated using the abbreviated
Modification of Diet in Renal Disease (MDRD) equation: eGFR (mL/
min/1.73 m
2)=e x p( 5 . 2 2 8 –1.154 × ln (SCr) − 0.203 × ln (age) −
(0.299 if female) + (0.192 if black). Induction was considered whether
the immunosuppressive was ALG/ATG or OKT3 or anti-IL-2R.
HCV infection was defined by the presence of HCV antibody
(ELISA2/3).
Statistical analysis
Statistical treatment of data was done with the support of SPSS version
17.0. Continuous variables were described using measures of central ten-
dency (mean, median) and measure of dispersion (standard deviation,
minimum and maximum). Categorical variables were described as abso-
lute and relative frequency.
The survival function was evaluated by Kaplan–Meier, Cox regression
and log-rank test, to study graft and patient survival, as well as the asso-
ciation between graft and patient survival and the presence of HCV+ or
the cohort (transplanted in 1990–94 or 1998–2002).
Results
Donor and recipient characteristics
Mean donor age was 42.39 ± 16.9 (range 12–86) years that
was significantly higher in HCV-negative 42.77 ± 16.9
than HCV-positive patients 39.98 ± 16.31 years (P <
0.001). Donor age significantly increased in the period
1998–2002, 45.35 ± 16.81 vs 3 7 . 5 6±1 5 . 9i n1 9 9 0 –94
(P < 0.001) in all patients and separated in HCV+ and
HCV− patients.
Mean recipient age was 46.6 ± 13.27 (range 18–78)
years; this also was significantly higher in HCV-negative
46.8 ± 13.3 years than HCV-positive patients 45.2 ±
12.8 years (P < 0.005). Recipient age increased signifi-
cantly in the period 1998–2002, 48.21 ± 13.4 vs 44.1 ±
12.6 years in 1990–94 (P < 0.001) in all patients and sep-
arately in HCV+ and HCV− patients.
Gender was 62.2% males and 37.8 females without dif-
ferences according to HCV status.
Re-transplantation was more frequent in 1998–2002
than 1990–94 (13.2% vs 10.6%, P < 0.05). In the subpop-
ulation of HCV+ patients, the frequency of re-transplants
was higher than HCV− patients (32.4% vs 9%, P < 0.001)
and notably was significantly higher in the modern period
(51.2% vs 21.8%, P < 0.001) in HCV-positive patients.
Pre-transplant panel-reactive antibodies (PRA) were sig-
nificantly higher in HCV+ than HCV-negative patients
(7.54 vs 3.79, P < 0.01), and the subpopulation of HCV-
positive PRA was higher in those transplanted in 1998–
2002 (10.68% vs 5.83%, P < 0.01). The percentage of pa-
tients with PRA >50% was higher in the HCV+ group
(4.4% vs 2%, P < 0.05).
Time on dialysis was higher in HCV+ patients (6.86 ±
5.3 vs 2.64 ± 2.89 year, P < 0.001) and in those trans-
planted in 1998–2002 HCV+ (8.4 ± 5.9 vs 5.9 ± 4.3 year,
P < 0.001) but not in the HCV− subpopulation.
HLA mismatching DR and B was higher in the modern
era: 38.6% vs 29.1% (P < 0.001) had two incompatibilities
in the HLA-B, and 11.3% vs 4.4% (P < 0.001) had two
mismatches in HLA-DR. In the subpopulation of HCV ,
the same happened with the locus DR.
The percentage of pre-transplant diabetes was low in the
whole group (5.5%), showing a higher frequency in HCV-
negative vs HCV-positive patients (5.9% vs 3.4%, P <
0.05). Interestingly, pre-transplant diabetes was higher in
the modern era in HCV-negative (6.8% vs 4.1%, P <
0.001) and HCV-positive patients comparing with the
1990–94 period (6.3% vs 1.7%, P < 0.001).
Immunosuppression
Induction therapy was more frequent in HCV+ patients
(39.8% vs 34.1%, P < 0.05). ALG/ATG was preferential-
ly used in 63% of them. Cyclosporine was used in
71.2%, MMF in 49%, and tacrolimus in 25% without dif-
ferences in HCV subpopulations. However, cyclosporine
was more used in HCV-positive patients (81.3% vs 69.5%,
P < 0.005).
Prevalence of HCV infection was decreasing progres-
sively from 27.7% in 1990 to 5.9% in 1998 (P < 0.001),
as we demonstrated in the previous analysis [5].
Delayed graft function, acute rejection, renal function and
proteinuria
Delayed graft function was higher in HCV-positive pa-
tients 38.5% vs 29.4%, P < 0.001, but with no difference
between periods.
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32.5% vs 27.3%, P < 0.01. Patients transplanted in
1990–94 suffered more acute rejection episodes than those
transplanted in the modern era (39.1% vs 21%, P < 0.001),
as well as in the two subpopulations HCV negative (39.8%
vs 20.6%, P < 0.001) and HCV positive (36.6% vs 25.2%,
P < 0.01). It is interesting to note that acute rejection in
HCV patients was higher than HCV-negative patients in
the modern era (25% vs 20.6%, P < 0.01). The majority
of acute rejection episodes were in the first year (84.6%).
Meanvalues of eGFR were lower in HCV+ vs HCV− pa-
tients from the second year post-transplant. From the first
year,therewas a much better GFR in thewholegroup trans-
planted in the period 1998–2002, including both HCV+
and HCV− patients. Serum creatinine (SCr) showed higher
mean values in HCV+ vs HCV− patients from the second
year post-transplant. From the first year, SCr was lower in
the whole group transplanted in the modern era, including
both HCV+ and HCV− patients.
Mean values of proteinuria were higher from the first
year in HCV+ vs HCV− patients. Proteinuria was lower
in the whole group of patients transplanted in the modern
era, but only in the second and in the third years post-
transplant (see evolution of eGFR, creatinine and protein-
uria in Figure 1).
Interestingly, the percentage of patients with at least one
graft biopsy during these 4 years was higher in HCV+ ver-
sus HCV− group: 34.6% vs 25%, P < 0.05. The indica-
tions of biopsy were worsening of renal function and/or
proteinuria in both groups of patients. Transplant glomer-
ulopathy and de novo glomerulonephritis were more fre-
quent in HCV patients (Table 1).
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Fig. 1. Renal function and proteinuria.
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Graft loss during the 4 years of follow-up was 7.2%, but
significantly higher in HCV+ vs HCV− patients: 12.1% vs
6.4%, P < 0.001. Therefore, graft survival was 92.8%
across the whole group. There were no differences in graft
survival in HCV+ patients comparing the period 1990–94
vs 1998–2002: 87.5% vs 93%, P = 0.084. However, in
HCV− patients, graft survival was significantly better in
the modern period: 95.3% vs 92.9%, P < 0.005. Causes
of graft loss are displayed in Table 2.
In the univariate analysis: donor age, recipient age, acute
rejection, HCV positivity, cohort (year of transplantation),
pre-transplant PRA, acute tubular necrosis, post-transplant
diabetes at 1year, therapy with steroids, induction, tacroli-
mus, cyclosporine, anti-IL2 R, value of proteinuria, serum
creatinine, eGFR, total cholesterol, systolic (SBP) and di-
astolic blood pressure (DBP), and body weight were statis-
tical significant factors for graft survival. These factors
were introduced in the Cox regression model analysis
showing that only serum creatinine and proteinuria at
1 year, acute rejection, HCV positivity, and SBP were in-
dependent risk factors for graft loss, while body weight,
GFR, recipient age and year of transplantation were pro-
tective factors for the graft (Table 2).
Patient survival
During the first 4 years of follow-up, 4.3% of the whole
group died, showing a decrease of death in the modern
era: 3.7% vs 5.2%, P < 0.05. Mortality was higher in
HCV+ vs HCV−:6 . 1 %vs 4%, P < 0.05, but there was
no difference in both periods: 1990–94 6.4% vs 5.7%
(P = NS) in 1998–2002.
Patient survival in thewholegroup was 96.3% showing a
significant difference between HCV-negative and HCV-
positive patients: 96.6% vs 94.5%, P < 0.05. Causes of
death are represented in Table 3. Ages of the patients who
died were higher in both groups, HCV+ and HCV−, in the
period 1998–2002.
In the univariate analysis, donor age, recipient age, acute
rejection, HCV+, proteinuria, serum creatinine, GFR, SBP,
DBP and treatment with steroids were associated factors
with mortality. Cox regression analysis including all sig-
nificant data in the univariate demonstrated that serum cre-
atinine and SBP at 1year, HCV+ and recipient age were
independent risk factors for patient death (Table 3).
Discussion
In the present national study performed in Spain, we show
the results of renal transplantation in patients with hepatitis
C antibody compared with patients HCV− in the period
1990–2002. At 4 years after transplantation, graft and pa-
tient survival were lower than HCV-negative patients, and
Table 2. Causes of graft loss and Cox regression analysis for graft loss
Causes of graft loss at the fourth year after renal transplantation
HCV(−) n = 227 HCV(+) n = 70 All n = 297
Biopsy-proven CAN 61 (30%) 22 (34.4%) 83 (30%)
No biopsy-proven CAN 68 (33.5%) 20 (31.3%) 88 (33%)
Death with functioning graft 10 (4.9%) 3 (4.7%) 13 (4.9%)
De novo glomerulonephritis 6 (3%) 4 (6.3%) 10 (3.7%)
Late acute rejection 13 (6.4%) 6 (9.4%) 19 (7.1%)
Recurrent original disease 16(7.9%) 4 (6.3%) 20 (7.5%)
Non-compliance 9 (4.4%) 0 (0) 9 (3.4%)
Others 20 (9.9%) 5 (2.8%) 25 (9.4%)
P =N S
Cox-regression analysis: factors for graft failure.
P-value OR CI 95% OR
Low–high
Serum creatinine at 1 year <0.001 1.937 1.563–2.401
Proteinuria at 1 year <0.001 1.360 1.272–1.454
SBP at 1 year <0.01 1.013 1.005–1.021
Body weight at 1 year <0.001 0.974 0.961–0.987
GFR at 1 year <0.001 0.969 0.952–0.987
Acute rejection <0.05 1.439 1.031–2.009
Recipient age <0.01 0.982 0.970–0.995
Hepatitis C antibody <0.001 1.702 1.264–2.291
Transplantation 1998–2002 <0.01 0.676 0.525–0.871
Table 1. Pathological lesions of graft biopsies
Diagnosis
HCV(−)
n = 463
HCV(+)
n = 140
ALL
n = 603
Transplant glomerulopathy 23 (5.0%) 16 (11.4%) 39 (6.5%)
De novo GN 24 (5.2%) 13 (9.3%) 37(6.1%)
Normal 22 (4.8%) 2 (1.4%) 24 (4.0%)
CAN la 65 (14.0%) 16 (11.4%) 81 (13.4%)
CAN lb 43 (9.3%) 5 (3.6%) 48 (8.0%)
CAN lla 60 (13.0%) 21 (15.0%) 81 (13.4%)
CAN llb 52 (11.2%) 18 (12.9%) 70 (11.6%)
CAN llla 27 (5.8%) 8 (5.7%) 35 (5.8%)
CAN lllb 17 (3.7%) 5 (3.6%) 22 (3.6%)
Others 57 (12.3%) 12 (8.6%) 69 (11.4%)
Acute rejection 35 (7.6%) 15 (10.7%) 50 (8.3%)
Recurrent disease 38 (8.2%) 9 (6.4%) 47 (7.8%)
P < 0.05
GN, glomerulonephritis; CAN, chronic allograft nephropathy.
ii44 J.M. Morales et al.remarkably, HCV+ patients exhibited a greater degree of
proteinuria and lower renal function from the first post-
transplant year. Comparison among the two periods
showed no difference in survival figures or renal function
and/or proteinuria in the two cohorts of HCV-positive pa-
tients. Fortunately, the prevalence of HCV infection in our
patients is decreasing progressively.
Graft survival at 4 years was lower in HCV patients, and
HCV infection was an independent risk factor for graft loss
at short time after transplantation. This is an interesting
finding because, in most series, graft survival is lower in
the long term [3,4,6]. In addition, proteinuria was higher,
and renal function was lower after the first year, which ex-
plains why these patients were biopsied more frequently
than HCV-negative patients. Also, the presence of HCV-
associated GN and transplant glomerulopathy were more
frequent in HCV patients. In this way, we showed that
HCV infection seems to be a risk factor for transplant
glomerulopathy as has been recently described by the
group of the Mayo Clinic in protocol biopsies [7]. In ad-
dition, acute tubular necrosis and acute rejection rate
were more frequent in HCV patients; particularly, acute
rejection was higher in the modern era. This incidence
of acute rejection could be explained because hyperim-
munized and re-transplants were more frequent in the
HCV+ population [8], because in low risk patients, the
presence of acute rejection is lower compared with
HCV-negative patients [9]. These factors, acute rejection,
hyperimmunization and re-transplantation are risk factors
for chronic rejection and transplant glomerulopathy.
Therefore, it is reasonable to think that HCV-positive pa-
tients could have an increased risk for chronic humoral
rejection and graft failure.
The presence of proteinuria is important because it is
well known that HCV infection is an independent risk fac-
tor for proteinuria [5,10]. We demonstrated that proteinuria
is higher than in the HCV− population, and accompanied
by a concomitant diminution of renal function after the first
year. These factors per se are risk factors for allograft fail-
ure [5,6] and clinically represent the early damage of the
allograft, mainly by chronic allograft nephropathy. So, in
protocol biopsies at 6 months, HCV infection was an inde-
pendent risk factor for graft loss [11] and for transplant
glomerulopathy [7]. Our data demonstrated that HCV in-
fection is associated with early greater rates of protein-
uria, lower renal function, chronic rejection, de novo GN
and graft loss. Therefore, HCV infection may be included
as a true risk factor for graft loss and chronic allograft ne-
phropathy/chronic rejection. In this way, pre-transplant
treatment with interferon could decrease the incidence of
chronic allograft nephropathy [12].
Patient survival at 4 years in the whole group trans-
planted in 1990–2002 is excellent. As expected, patient
survival was lower in HCV+ patients compared with
HCV negative, but in spite of this mortality can be con-
sidered low taking into consideration the presence of the
chronic condition of HCV infection. The most important
series demonstrated that, in the short term, patient surviv-
al is similar to non-infected renal transplant patients, and
in the long term, mortality is higher in HCV+ patients
[3,6,13,14]. Notably, in our series, mortality is earlier
and more elevated at 4 years, very similar to recently pub-
lished American findings [15]. In patients transplanted in
the modern era, mortality was a little bit lower than in
1990–94 but without statistical differences. Cardiovascu-
lar, infections and neoplasia were the most frequent causes
of death in our patients, and liver disease was higher in
HCV+. Cox regression analysis showed that, once again,
HCV+ was an independent risk factor for mortality at
4 years together with recipient age, Scr and DBP at 1year.
Therefore, a good blood pressure control and an im-
provement of renal function are mandatory to improve
this early mortality. In these patients, the presence of
post-transplant diabetes, proteinuria and a lower renal
function are cardiovascular risk factors that could explain
why heart disease is the first cause of death. Also, the lon-
ger time on dialysis and the presence of arterial hyperten-
sion could also contribute.
The main limitation of this study was that we have no
information of HCV RNA at transplantation and in the fol-
low-up. Also, there is no information about liver enzyme
values or liver biopsy. Therefore, because we do not know
how many patients had viraemia and if they had liver fi-
brosis, we cannot demonstrate the role of liver disease in
survival figures [16]. In spite of this, our work is the lon-
gest numerically and in follow-up in renal transplant pa-
tients showing the role of HCV infection on early graft
failure.
In summary, renal transplantation is an effective therapy
for patients with HCV infection, with survival figures that
are good but inferior to those obtained in HCV-negative
patients in the short term. Notably, HCV-associated renal
damage appears early with proteinuria and elevated serum
creatinine showing chronic allograft nephropathy, trans-
plant glomerulopathy and less frequently HCV-associated
de novo GN. We suggest that HCV infection should be rec-
ognized as a true risk factor for graft failure, and preven-
tive measures could include pre-transplant therapy with
interferon in viraemic patients [17].
Table 3. Causes of mortality and Cox regression analysis for patient
death
Causes of death at the fourth year after renal transplantation
HCV(−)
n = 149
HCV(+)
n =3 6
All
n = 185
Heart disease 32 (25.4%) 11(59.3%) 43 (27.9%)
Neoplasia 30 (23.8%) 1 (3.6%) 28 (18.2%)
Infection 27 (4.4%) 6 (4.4%) 36 (23.4%)
Liver disease 1 (0.8%) 2 (7.1%) 3 (1.9%)
Others 36 (28.6%) 8 (28.6%) 44 (28.6%)
P < 0.05
Risk factors for mortality at the fourth year after real transplantation:
Cox regression analysis
P-value OR CI 95% OR
Low–high
Serum creatinine at 1 year <0.001 1.905 1.573–2.306
Diastolic blood pressure <0.05 1.016 1.000–1.032
Hepatitis C antibody <0.05 1.684 1.110–2.557
Recipient age <0.001 1.064 1.048–1.081
Renal transplantation in patients with HCV antibody ii45Conflict of interest statement. None declared.
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